Livzon Bio

Livzon Bio is the biologics innovation arm of Livzon Pharmaceutical Group focused on discovery, development, and industrialization of macromolecular therapeutics. The company develops monoclonal antibodies, antibody-like drugs, bispecific antibodies, antibody-drug conjugates, CAR-T therapies, vaccines, and other biologics across autoimmune disease, oncology, assisted reproduction, and infectious disease prevention. Its disclosed commercialized products include a recombinant human chorionic gonadotropin injection in China, the COVID-19 fusion protein vaccine V-01, and tocilizumab injection marketed as Anweitai for rheumatoid arthritis, cytokine release syndrome, and systemic juvenile idiopathic arthritis. Livzon Bio operates from Zhuhai and has built in-house capabilities spanning antibody humanization, cell line screening, large-scale cell culture, purification, formulation, analytical testing, and quality control. It appears to function as a majority-controlled Livzon Group subsidiary rather than an independent public biotech.